Abstract
Introduction The coronavirus disease 2019 (COVID-19) epidemic has been emerged worldwide. Although several medications have been approved for treating moderate-to-severe COVID-19, no treatment strategy has been established for mild COVID-19 patients who do not require oxygen administration. The spread of SARS -CoV-2 has been mostly through patients with mild COVID-19; therefore, treating patients with mild COVID-19 is critical in society. Clarithromycin is a macrolide antimicrobial agent that has been widely used for bacterial respiratory infectious diseases. Clarithromycin also acts an immunomodulating drug and suppresses cytokine storms in viral respiratory diseases, including influenza infection. In this study, we aimed to evaluate the efficacy of clarithromycin in patients with mild COVID-19.
Methods and analysis This is a multicenter, open-label, randomized controlled, 3-armed parallel group comparison, exploratory trial. Subjects with mild COVID-19 pneumonia who did not require oxygen administration were enrolled and randomly assigned in a 1:1:1 ratio to Group A (administration of clarithromycin 800 mg/day), Group B (administration of clarithromycin 400 mg/day), or Group C (standard treatment without clarithromycin). The primary endpoint was the number of days required to improve clinical symptoms as measured by the severity score. Secondary endpoints included days to recover the body temperature, proportion of subjects with oxygen administration, inflammatory cytokines, viral load, serum immunoglobulins, peripheral blood lymphocytes, blood biomarkers, and pneumonia infiltrations.
Ethics and dissemination The study protocol was approved by the Clinical Research Review Board of Nagasaki University in accordance with the Clinical Trials Act in Japan. The study will be conducted in accordance with the Declaration of Helsinki, the Clinical Trials Act, and other current legal regulations in Japan. Written informed consent will be obtained from all participants. The results of this study will be reported as journal publications.
Registration This study was registered at the Japan Registry of Clinical Trials (registration number: jRCTs071210011).
Strengths and limitations of this study
This is the first randomized controlled trial to evaluate the efficacy of clarithromycin against COVID-19 pneumonia, especially in patients with mild COVID-19 pneumonia who do not require oxygen administration.
To date, no treatment strategy has been established for mild COVID-19 pneumonia.
The major limitations of this study are its exploratory nature and relatively small sample size.
Another limitation is the open-label study design and generalizability because this study was conducted only in Japan with Japanese patients.
Competing Interest Statement
Kazuhiro Yatera has received grants from Bayer Yakuhin, Ltd., and has received honoraria for scientific lecture presentations, speaker bureaus, manuscript writing, or educational events from AstraZeneca K.K., Kyorin Pharmaceutical Co., Ltd., Boehringer Ingelheim Pharmaceuticals, GlaxoSmithKline K.K., and Novartis Pharma K.K. Hiroshi Mukae has received grants from Taisho Pharmaceutical Co., Ltd., Boehringer Ingelheim Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Kyorin Pharmaceutical Co., Ltd., has received honoraria for scientific lecture presentations, speaker bureaus, manuscript writing, or educational events from Taisho Pharmaceutical Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., MSD K.K., Boehringer Ingelheim Pharmaceuticals, and Kyorin Pharmaceutical Co., Ltd., and has received donation from FUJIFILM Toyama Chemical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd. All funding agencies play no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors declare no conflict of interest.
Clinical Trial
jRCTs071210011
Clinical Protocols
https://jrct.niph.go.jp/en-latest-detail/jRCTs071210011
Funding Statement
This study was financially supported by the Taisho Pharmaceutical Co., Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study and its protocol were approved by the Clinical Research Review Board of Nagasaki University (approval no. CRB20-027) in accordance with the Clinical Trials Act of Japan. The study was conducted in accordance with the Declaration of Helsinki, the Clinical Trials Act, and other current legal regulations in Japan.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data is available public after the completion of this study, because the study protocol does not include the statement to share the data public, and the ethics committee did not approve the data sharing.
